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1. Introduction
The purpose of presenting this book is to provide an insight into various spectrum symptoms 
that the women present with pelvic floor disorders or/dysfunctions. Pelvic floor disorders 
and dysfunctions are overlapping terms. Pelvic floor disorders (PFDs) include urinary (UI) 
and anal incontinence (AI) and pelvic organ prolapse (POP) [1]. To understand pelvic floor 
dysfunctions, one must appreciate the role of the pelvic floor muscle (PFM). When the PFM 
is neglected or injured, one or multiple forms of pelvic floor dysfunctions may result, such as 
bladder and bowel incontinence, obstructive micturition, constipation, pelvic pain and sexual 
dysfunction, POP and/or low back pain [2].
Pelvic floor dysfunction symptoms of vaginal pain and backache is due to hypertonic pel-
vic floor muscle which is defined as general increase in muscle tone that can be associated 
with either elevated contractile activity and/or passive stiffness in the muscle [3]. Most of 
women present with pelvic floor defects/relaxation symptoms but pelvic floor dysfunction 
also include non-relaxing pelvic floor symptoms which are not widely recognized. Unlike in 
pelvic floor disorders caused by relaxed muscles (e.g., pelvic organ prolapse or urinary incon-
tinence, both of which often are identified readily), women affected by no relaxing pelvic floor 
dysfunction may present with a broad range of nonspecific symptoms. These may include 
pain and problems with defecation, urination, and sexual function, which require relaxation 
and coordination of pelvic floor muscles and urinary and anal sphincters. These symptoms 
may adversely affect the quality of life [4].
2. Etiology, pathophysiology, and risk factors
There are many theories which explain the urinary, fecal incontinence, and pelvic organ pro-
lapse. The risk factors such as obesity, high parity, advanced age, and life style have been 
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mentioned but we still lack a real understanding of the pathophysiology of pelvic floor dis-
orders. Although it seems apparent that multiple factors combine in each woman for the 
development of a clinical condition like prolapse or UI, these need to be identified prior to 
treatment to avoid recurrence of disease.  The genetic predisposition aggravated by acquired 
risk factors, such as childbirth, hormonal changes, and aging predisposes the women to 
PFD. There is a lack of strong evidence for this hypothesis. Findings of epidemiologic studies 
are frequently inconsistent. A clearer comprehension of the pathophysiology responsible for 
PFD is clinically relevant on different levels. First, identifying the patient population at risk 
through screening of known polymorphism can lead to preventive strategies and the avoid-
ance of contributing risk factors. Second, it may allow the development of interventional ther-
apies where we can locally modify the extracellular matrix (ECM) composition of pelvic floor 
muscles and ligaments. Future research should then focus on understanding what processes 
control ECM remodeling and aging using specific and standardized measurement methods 
and tracing them back to genetic transcription [5].
3. Clinical symptoms and diagnosis
The pelvic floor disorders present with varied symptoms which are related to UI, FI, and 
POP. Although the women may present with clinical symptom of POP but they usually have 
backache, vaginal discharge in association with both urinary frequency and urgency and 
urinary leak while straining or during sexual intercourse. The fecal symptoms may occur 
after iatrogenic injury to anal sphincters during child birth. The prevalence of pelvic floor 
dysfunction is 24%, with 16% of women experiencing urinary incontinence, 9% experiencing 
fecal incontinence, and 3% experiencing pelvic organ prolapse [6]. The clinical presentation of 
pelvic floor disorders in an urogynecology clinic often lead to a diagnosis where a multidisci-
plinary approach is usually required for management of a case, which may include evaluation 
by an urogynecology radiologist. Complete diagnosis by clinical examination alone can be 
challenging, particularly in cases of posterior vaginal wall prolapse and/or a multicompart-
ment problem. Imaging has become an important complementary tool in the assessment of 
pelvic floor disorders, and dynamic pelvic floor magnetic resonance imaging (MRI), or MR 
defecography, has evolved as one of the essential imaging techniques [7].
MRI can simultaneously noninvasively evaluate all pelvic floor compartments and provide 
information about muscles and ligaments with great contrast resolution, without the use of 
ionizing radiation and with minimal patient discomfort [8].
4. Treatment
Since pelvic floor disorders present with site-specific defects, clinical presentation varies with 
grades of disease. The management really depends on the impact of disease on women’s quality 
of life. The first line of management is always conservative which includes pelvic floor muscle 
physiotherapy, avoidance of risk factors like constipation and smoking but usually women do 
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require a definitive surgical treatment and few women may need a second procedure during 
their life time. Multi-compartment pelvic floor disorders are now increasingly being evaluated 
and managed jointly by urogynaecologists and colorectal surgeons in a designated pelvic floor 
clinic. Before embarking treatment, a comprehensive tool for symptom assessment or the use 
of a standard questionnaire is required. Patient should be counseled in detail about diagnosis, 
treatment options, success rate, and complications of a selected procedure.
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